Johnson & Johnson's Janssen Pharmaceutical unit has a long heritage and established commercial position in multiple myeloma – where the company is now trying to develop curative regimens – but the firm is also working to expand more broadly in solid tumor indications, including non-small cell lung cancer, bladder cancer and earlier-stage prostate cancer.
Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.
